Sunshine Biopharma signs exclusive worldwide license with U. Arizona for PLpro COVID-19 treatment

Sunshine Biopharma Inc.

License grants exclusive worldwide rights to PLpro protease inhibitors of SARS-CoV-2 (COVID-19).
Company pays 3% royalty on net sales and 30% of sublicensee revenues.
Milestone payments required; University can terminate if milestones not met.
Collaboration began February 2022; option to license was exercised.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sunshine Biopharma Inc. entered into Exclusive Patent License Agreement with Arizona Board of Regents on behalf of the University of Arizona (effective 2023-02-24).

Action: entry
Agreement: license
Counterparty: Arizona Board of Regents on behalf of the University of Arizona
Effective: 2023-02-24

Exact text from the filing

On February 24, 2023, Sunshine Biopharma, Inc. (the “Company”) entered into an Exclusive Patent License Agreement (the “License Agreement”) with Arizona Board of Regents on behalf of the University of Arizona (the “University”).

View on SEC.gov

Browse all material agreements →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-001172

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.